1.Date of occurrence of the event:2021/11/18
2.Method of the current increase (decrease) in investment:
Purchase Non-voting Convertible Preferred Shares of Medtech Holdings,
indirectly invest into Peter’s Technology (Suzhou) Co., Ltd.
3.Amount, unit price, and total monetary amount of the transaction:
Amount and Unit Price: as per actual issued units and price;
Total Monetary Amount: up to US$15M
4.Company name of the mainland Chinese investee:
Peter’s Technology (Suzhou) Co., Ltd.
5.Paid-in capital of aforementioned mainland Chinese investee:
RMB 64.2 Million
6.Amount of capital increase currently planned for the aforementioned
mainland Chinese investee:Not Applicable
7.Main businesses of the aforementioned mainland Chinese investee:
WWire harness assemblies, components, and assemblies for medical devices
8.Type of CPA opinion in the latest annual financial statements of the
aforementioned mainland Chinese investee:Unqualified Opinion
9.Total equity of the aforementioned mainland Chinese investee in the latest
annual financial statements:RMB 114.6 Million
10.Amount of profit/loss of the aforementioned mainland Chinese investee in
the latest annual financial statements:RMB 36.4 Million
11.Amount of actual investment in the aforementioned mainland Chinese
investee, up to the present moment:Nil
12.Trading counterparty and its relationship with the Company:
Trading Counterparty: Medtech Holdings; Its relationship with the
Company: Related party as defined in the Regulations Governing the
Preparation of Financial Reports by Securities Issuers to the
Company after capital injection
13.Where the trading counterparty is a related party, announcement shall
also be made of the reason for choosing the related party as trading
counterparty and the identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous date and monetary
amount of transfer:
Reason for choosing: For the need of investment business development;
No previous transfer.
14.Where an owner of the underlying assets within the past five years has
been a related party of the Company, the announcement shall also include the
date and price of acquisition and disposal by the related party, and its
relationship with the Company at the time of the transaction:
Not Applicable
15.Profit (or loss) upon disposal:Not Applicable
16.Terms of delivery or payment (including payment period and monetary
amount), restrictive covenants in the contract, and other important terms
and conditions:Per contract
17.The manner in which the current transaction was decided, the reference
basis for the decision on price, and the decision-making unit:
Mutual agreement; Board of directors
18.Broker:Nil
19.Concrete purpose of the acquisition or disposal:
For the need of investment business development
20.Any dissenting opinions of directors to the present transaction:
Nil
21.Whether the counterparty of the current transaction is a related party:
YES
22.Date of the board of directors resolution:2021/11/18
23.Date of ratification by supervisors or approval by
the Audit Committee:NA
24.Total amount of investment in mainland China (including the current
investment) approved by the Investment Commission, up to the present moment:
NTD 6,750,416,717
25.Ratio of the total amount of investment in mainland China (including the
current investment) approved by the Investment Commission, up to the present
moment, to the paid-in capital on the latest financial statements:
4.78%
26.Ratio of the total amount of investment in mainland China (including the
current investment) approved by the Investment Commission, up to the present
moment, to the total assets on the latest financial statements:2.58%
27.Ratio of the total amount of investment in mainland China (including the
current investment) approved by the Investment Commission, up to the present
moment, to equity attributable to owners of the parent on the latest
financial statements:3.17%
28.Total amount of actual investment in mainland China, up to the present
moment:NTD 4,861,553,405
29.Ratio of the total amount of actual investment in mainland China, up to
the present moment, to the paid-in capital on the latest financial
statements:3.24%
30.Ratio of the total amount of actual investment in mainland China, up to
the present moment, to the total assets on the latest
financial statements:1.75%
31.Ratio of the total amount of actual investment in mainland China, up to
the present moment, to equity attributable to owners of the parent on the
latest financial statements:2.15%
32.Amount of recognized profit (loss) on investment in mainland China for
the last three years:NTD 3,525,889,000
33.Amount of profit remitted back to Taiwan for the last
three years:NTD 4,298,220,782
34.Whether the CPA issued an unreasonable opinion regarding the current
transaction:Nil
35.Name of the CPA firm:YANGTZE CPAS & CO.
36.Name of the CPA:Hu, Hsiang-Ning
37.Practice certificate number of the CPA:191
38.Any other matters that need to be specified:
1) USD 1 = NTD 27.84 (as of 2021/11/1)
2) “GM” is short for “CDIB Global Markets Limited”.
3) “Medtech Holdings” is short for “CDIB Medtech Holdings Limited”
4) “CPS” is short for “Convertible Preferred Shares”
5) This investment will be proceeded (including the funding) after
MOEAIC’s approval.